.png?width=2400&height=263&name=Emergent-BioServices_CMYK_Logo-Tagline-Lockup%20(2).png "Emergent BioSolutions CDMO"){kind=logo}
06.02.2020
Emergent Continues to Expand Role in Support of Development and Manufacturing of COVID-19 Vaccines
Emergent BioSolutions recently announced that it has been issued a task order under an existing contract with the Biomedical...
06.01.2020
Emergent BioSolutions Joins U.S. Government’s Warp Speed Program in Landmark Public-Private CDMO Partnership for COVID-19 Vaccine Development and Manufacturing
- Emergent and HHS expand 2012 CIADM public-private partnership with task order valued at approximately $628 million for rapid...
04.27.2020
May 4th Webinar: Rapid Readiness for Pandemic Response
Watch our latest webinar on the topic of how drug developers can maximize capacity, capabilities and expertise for pandemic...
04.27.2020
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
GAITHERSBURG, Md., April 23, 2020 (GLOBE NEWSWIRE)
Emergent BioSolutions Inc. (NYSE:EBS) today announced an agreement whereby...
04.17.2020
Webinar: Finding Solutions for public health threats: COVID-19
What are innovators doing to speed up the path to treating and preventing COVID-19?
The novel coronavirus has quickly taken...
03.23.2020
Novavax + Emergent: In the news
Original news coverage of Novavax's agreement with Emergent BioSolutions to manufacture and develop an experimental oral vaccine...